EP0896506A4 - Verfahren zum induzieren der möglichkeit einer immunantwort - Google Patents

Verfahren zum induzieren der möglichkeit einer immunantwort

Info

Publication number
EP0896506A4
EP0896506A4 EP97916046A EP97916046A EP0896506A4 EP 0896506 A4 EP0896506 A4 EP 0896506A4 EP 97916046 A EP97916046 A EP 97916046A EP 97916046 A EP97916046 A EP 97916046A EP 0896506 A4 EP0896506 A4 EP 0896506A4
Authority
EP
European Patent Office
Prior art keywords
inducing
possibility
immune response
immune
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97916046A
Other languages
English (en)
French (fr)
Other versions
EP0896506A1 (de
Inventor
Richard L Edelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP0896506A1 publication Critical patent/EP0896506A1/de
Publication of EP0896506A4 publication Critical patent/EP0896506A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP97916046A 1996-03-22 1997-03-18 Verfahren zum induzieren der möglichkeit einer immunantwort Withdrawn EP0896506A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62110996A 1996-03-22 1996-03-22
US621109 1996-03-22
PCT/US1997/004285 WO1997034472A1 (en) 1996-03-22 1997-03-18 Methods for inducing immune responsiveness in a subject

Publications (2)

Publication Number Publication Date
EP0896506A1 EP0896506A1 (de) 1999-02-17
EP0896506A4 true EP0896506A4 (de) 2003-06-18

Family

ID=24488765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97916046A Withdrawn EP0896506A4 (de) 1996-03-22 1997-03-18 Verfahren zum induzieren der möglichkeit einer immunantwort

Country Status (5)

Country Link
EP (1) EP0896506A4 (de)
JP (1) JP2000508628A (de)
AU (1) AU2331597A (de)
CA (1) CA2249412A1 (de)
WO (1) WO1997034472A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
AU782391B2 (en) 1999-04-20 2005-07-21 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US7109031B2 (en) 1999-04-20 2006-09-19 Yale University Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
DE19960705A1 (de) * 1999-12-16 2001-06-21 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur Herstellung eines autologen Immunisierungsimpfstoffes gegen Krebserkrankungen (Tumorvakzine)
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
DE10053783B4 (de) * 2000-07-10 2007-06-14 Eppendorf Ag Verfahren zur Modifizierung von dendritischen Zellen
US7727523B2 (en) 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
CA2457015C (en) * 2001-08-13 2012-03-13 Richard L. Edelson Method for inducing selectively suppressed immune response
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
JP2023552440A (ja) * 2020-12-07 2023-12-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー アトラクチレノリドｉを用いて癌細胞を免疫攻撃に対して感受性にする方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1994011016A1 (en) * 1992-11-18 1994-05-26 Yale University Specific immune system modulation
EP0333606B1 (de) * 1988-03-15 1994-06-08 Yeda Research And Development Company Limited Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0333606B1 (de) * 1988-03-15 1994-06-08 Yeda Research And Development Company Limited Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1994011016A1 (en) * 1992-11-18 1994-05-26 Yale University Specific immune system modulation
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERGER CAROLE L ET AL: "Transimmunization, a novel approach for tumor immunotherapy.", TRANSFUSION AND APHERESIS SCIENCE, vol. 26, no. 3, June 2002 (2002-06-01), June, 2002, pages 205 - 216, XP002238289, ISSN: 1473-0502 *
HSU F J ET AL: "VACCINATION OF PATIENTS WITH B-CELL LYMPHOMA USING AUTOLOGOUS ANTIGEN-PULSED DENTRITIC CELLS", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 2, no. 1, 1996, pages 52 - 58, XP000605401, ISSN: 1078-8956 *
See also references of WO9734472A1 *
STORKUS W J ET AL: "Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.", JOURNAL OF IMMUNOTHERAPY: OFFICIAL JOURNAL OF THE SOCIETY FOR BIOLOGICAL THERAPY. UNITED STATES AUG 1993, vol. 14, no. 2, August 1993 (1993-08-01), pages 94 - 103, XP009009060, ISSN: 1053-8550 *

Also Published As

Publication number Publication date
CA2249412A1 (en) 1997-09-25
WO1997034472A1 (en) 1997-09-25
AU2331597A (en) 1997-10-10
JP2000508628A (ja) 2000-07-11
EP0896506A1 (de) 1999-02-17

Similar Documents

Publication Publication Date Title
DE69233524D1 (de) Verfahren zum Steuern der Bremsen
DE69325218D1 (de) Verfahren zum wiederentbindbaren metallischen Verbinden
DE69706613D1 (de) Verfahren zum Liefern einer ungleichmässigen Strahlung
ATE191888T1 (de) Verfahren zum lösen von geklebten scheiben
DE69432015D1 (de) Verfahren
DE69735933D1 (de) Verfahren zum dynamischen einstellen von branderkennungskriterien
DE69736845D1 (de) Verfahren zum spritzgiessen einer orthese
DE69508921D1 (de) Verfahren zum nachweis von staphylokokken
DE69125441D1 (de) Verfahren zum Gennachweis
DE69532262D1 (de) Verfahren zum Mehrfachsenden
DE69719805D1 (de) Verfahren zum erzeugen von elastischen höckern
DE69302420D1 (de) Verfahren zum Fotoformen
DE69727714D1 (de) Verfahren zum Verbinden von Teilen
DE69207580D1 (de) Verfahren zum DNS-Nachweis
EP0896506A4 (de) Verfahren zum induzieren der möglichkeit einer immunantwort
DE69731707D1 (de) Verfahren zum Korrigieren von der ungleichen Position einer Informationsscheibe
DE59704267D1 (de) Verfahren zum Steuern einer Hängeförderanlage
DE69211850D1 (de) Verfahren zum löten
DE69719610D1 (de) Verfahren zum Nachweis von Kreatinin
DE69325382D1 (de) Verfahren zur oberflächenmodifikation
DE59812633D1 (de) Verfahren zum Verbinden von Bauteilen
DE69522745D1 (de) Verfahren zum Abbau von Polysiloxanen
DE69720843D1 (de) Verfahren zum Handhaben von Gegenständen
DE59207798D1 (de) Verfahren zum honen von bohrungen
DE69306782D1 (de) Verfahren zum verbinden von perfluorelastomeren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001